Angela B. Smith, MD, MS, describes her institution’s early clinical experience with mitomycin-containing reverse thermal gel (Jelmyto).
In this video, Angela B. Smith, MD, MS, also outlines side effects of Jelmyto that urologists should watch for. Smith is vice chair of academic affairs, director of urologic oncology, and associate professor of urology at UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.